Darbepoetin alfa

(Aranesp®)

Aranesp®

Latest News

loading GIF

Drug updated on 5/17/2024

Dosage FormInjection (intravenous/subcutaneous; 25 mcg, 40 mcg, 60 mcg, 100 mcg, 200 mcg and 300 mcg); Injection (intravenous/subcutaneous; 10 mcg/0.4 mL, 25 mcg/0.42 mL, 40 mcg/0.4 mL, 60 mcg/0.3 mL, 100 mcg/0.5 mL, 150 mcg/0.3 mL, 200 mcg/0.4 mL, 300 mcg/0.6 mL, and 500 mcg/1 mL)
Drug ClassErythropoiesis-stimulating agents
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and patients not on dialysis.
  • Indicated for the treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Darbepoetin alfa (Aranesp) is recommended for the management of anemia due to Chronic Kidney Disease (CKD) in both dialysis and non-dialysis patients, as well as for anemia resulting from myelosuppressive chemotherapy. It is effective in preventing blood transfusions in adults with CKD, demonstrating similar efficacy to other erythropoiesis-stimulating agents such as epoetin alfa and beta.
  • The information was derived from three systematic reviews/meta-analyses that compared Aranesp's safety and efficacy against placebo, other ESAs like epoetin alfa/beta, and novel treatments including vadadustat.
  • In terms of mortality risk associated with its use, darbepoetin alfa shows no significant difference when compared to a placebo or other evaluated ESAs, indicating comparable safety concerns related to mortality.
  • However, darbepoetin may increase the odds of hypertension more than a placebo does. This potential side effect is common among different erythropoiesis-stimulating agents used for treating anemia due to CKD.
  • When comparing newer treatments like vadadustat or Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), there is no significant difference between them and darbepoetin alfa regarding hemoglobin level elevation or all-cause mortality rates; however, vadadustat might be slightly less effective at raising hemoglobin levels, specifically within dialysis-dependent chronic kidney disease patients.
  • The studies considered various patient populations segmented into nondialysis-dependent (NDD) and dialysis-dependent (DD). Across these subgroups, Aranesp maintains a consistent efficacy profile while also indicating a possible increased risk of hypertension, which warrants specific considerations during treatment management.